Nova Eye Medical Ltd
ASX:EYE
Intrinsic Value
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. [ Read More ]
The intrinsic value of one
EYE
stock under the Base Case scenario is
0.52
AUD.
Compared to the current market price of 0.27 AUD,
Nova Eye Medical Ltd
is
Undervalued by 48%.
Nova Eye Medical Ltd's market capitalization is 61.8m AUD.
EYE stock price is 0.27 AUD.
EYE stock price (0.27 AUD) is 48% less than its Intrinsic Value (0.52 AUD).
EYE. Open DCF Valuation
EYE has upside potential of 127% compared to the average analyst price target.
Open Wall St Estimates
EYE's Revenue has grown by an exceptional 24% over the past 12 months.
EYE's short-term assets (9m AUD) exceed its short-term liabilties (6m AUD).
EYE's Revenue has been growing by 15% per year for the last 3 years.
EYE's ROE (Return on Equity) has significantly decreased in the last 3 years from 71% to -68%.
EYE's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -18% to -70%, and is approaching profitability.
EYE's Revenue is forecast to grow at a rate of 31% per year over the next 3 years.
EYE has negative Operating Income for the last twelve months.
EYE has negative Net Income for the last twelve months.
EYE's ROE (Return on Equity) for the past 12 months is negative and is equal to -68%.
EYE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -70%.
EYE's Altman Z-Score is very low and is equal to 1.73.
EYE has positive Gross Profit for the last twelve months.
EYE has negative Free Cash Flow for the last twelve months.
EYE's long-term assets (24m AUD) exceed its long-term liabilties (7m AUD).
EYE's D/E (Debt to Equity) is very low and is equal to 0.03.
EYE has negative three-year average ROE (Return on Equity): -20%. The company is not efficient at transforming stockholders' equity into net income.
EYE has negative three-year average ROIC (Return on Invested Capital): -38%. The company is not efficient at using invested capital to generate operating income.
EYE has negative Net Debt. This means that the company has more cash and short-term investments (3m AUD) than debt (559k AUD).
EYE earns more than enough operating income (-16m AUD) to safely cover interest payments on its debt (-37k AUD).
Valuation Backtest
Nova Eye Medical Ltd
Run backtest to discover the historical profit from buying and selling
EYE
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Nova Eye Medical Ltd
Balance Sheet Decomposition
Nova Eye Medical Ltd
| Current Assets | 9.2m |
| Cash & Short-Term Investments | 2.6m |
| Receivables | 2.2m |
| Other Current Assets | 4.4m |
| Non-Current Assets | 14.6m |
| PP&E | 2m |
| Intangibles | 12.5m |
| Other Non-Current Assets | 70k |
| Current Liabilities | 6.3m |
| Accounts Payable | 4.2m |
| Other Current Liabilities | 2.1m |
| Non-Current Liabilities | 559k |
| Long-Term Debt | 559k |
Earnings Waterfall
Nova Eye Medical Ltd
|
Revenue
|
18.7m
AUD
|
|
Cost of Revenue
|
-1.8m
AUD
|
|
Gross Profit
|
16.9m
AUD
|
|
Operating Expenses
|
-33.3m
AUD
|
|
Operating Income
|
-16.5m
AUD
|
|
Other Expenses
|
2.2m
AUD
|
|
Net Income
|
-14.3m
AUD
|
Free Cash Flow Analysis
Nova Eye Medical Ltd
EYE Profitability Score
Profitability Due Diligence
Nova Eye Medical Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Nova Eye Medical Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
EYE Solvency Score
Solvency Due Diligence
Nova Eye Medical Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Nova Eye Medical Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EYE Price Targets Summary
Nova Eye Medical Ltd
According to Wall Street analysts, the average 1-year price target for
EYE
is 0.61 AUD
with a low forecast of 0.61 AUD and a high forecast of 0.63 AUD.
Shareholder Return
EYE Price
Nova Eye Medical Ltd
| Average Annual Return | -11.11% |
| Standard Deviation of Annual Returns | 36.74% |
| Max Drawdown | -86% |
| Market Capitalization | 61.8m AUD |
| Shares Outstanding | 228 797 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Nova Eye Medical Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia and currently employs 130 full-time employees. The firm is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The firm's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).
Contact
IPO
Employees
Officers
The intrinsic value of one
EYE
stock under the Base Case scenario is
0.52
AUD.
Compared to the current market price of 0.27 AUD,
Nova Eye Medical Ltd
is
Undervalued by 48%.
You don't have any saved screeners yet
